CoChat
Cited by 185

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma

Open access
Kim, Chang Gon, Kim, Chan, Yoon, Sang Eun, Kim, Kyung Hwan, Choi, Seong Jin, Kang, Beodeul, Kim, Hye Ryun, Park, Su-Hyung, Shin, Eui-Cheol, Kim, Yeun-Yoon, Kim, Dae Jung, Chung, Hyun Cheol, Chon, Hong Jae, Choi, Hye Jin, Lim, Ho Yeong · 2021 · Journal of Hepatology

Abstract

BACKGROUND AND AIMS PD-1 inhibitor treatment can cause hyperprogressive disease (HPD), but the incidence, outcome, and predictive factors of HPD are unknown in hepatocellular carcinoma (HCC) patients treated with PD-1 blockade. Here, we assessed existence and factors predictive of HPD in advanced HCC patients treated with nivolumab. METHODS Advanced HCC patients treated with nivolumab (n=189) were enrolled. Occurrence of HPD was investigated using tumour growth dynamics based on tumour growth kinetics (TGK) and tumour growth rate (TGR) before and after treatment or time to treatment failure. We additionally analysed patients treated with regorafenib (n=95) or best supportive care (BSC)/placebo (n=103) after progression with sorafenib for comparison of tumour growth dynamics. RESULTS A fraction of patients showed flare-up of tumour growth upon PD-1 blockade, indicating the occurrence of HPD. Based on distinct patterns of disease progression exclusively observed in nivolumab, but not in regorafenib or BSC/placebo-treated cohort, we determined 4-fold increases in TGK and TGR ratios and 40% increase in TGR as cut-off values to define HPD and found that 12.7% of the patients (24/189) treated with nivolumab met all these criteria. Patients with HPD had worse progression-free survival (hazard ratio [HR]: 2.194; 95% confidence interval [CI]: 1.214-3.964) and overall survival (HR: 2.238; 95% CI: 1.233-4.062) compared with patients with progressive disease without HPD. More than 90% of patients with HPD missed the opportunity for subsequent treatment because of rapid clinical deterioration. An elevated neutrophil-to-lymphocyte ratio (> 4.125) was associated with HPD and an inferior survival rate. CONCLUSIONS HPD exists in a fraction of HCC patients who received PD-1 blockade. Analyses of the baseline immune profile and on-treatment tumour growth dynamics could promote optimal patient selection and earlier identification of rapid tumour growth induced by PD-1 inhibitors in HCC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.08.010

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 185

Metadata

Authors
Kim, C. G., Kim, C., Yoon, S. E., Kim, K. H., Choi, S. J., Kang, B., Kim, H. R., Park, S.-H., Shin, E.-C., Kim, Y.-Y., Kim, D. J., Chung, H. C., Chon, H. J., Choi, H. J., & Lim, H. Y.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2021-02
Volume
74
Issue
2
Pages
350-359
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3049075450
Cited by
185
References
13
FWCI
9.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.